ViaCyte Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH140971D
- Pages: 31
- November 2018
- Total Views:1146
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
ViaCyte Inc (ViaCyte), formerly Novocell Inc is a regenerative medicine company that centres on the development of cell replacement therapies for the treatment of diabetes. The company's pipeline products portfolio includes VC-01, which is being developed as a therapy for T1D patients who have minimal to no insulin-producing beta cell function; and PEC-Direct, for type 1 diabetes patients that have glycemic lability, hypoglycemic episodes, and impaired hypoglycemia awareness. Its PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device. The company works in partnership with academic, commercial and not-for-profit institutions. ViaCyte is headquartered in San Diego, California, the US.
ViaCyte Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViaCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ViaCyte Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
ViaCyte Raises USD10 Million in Financing 11
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 12
ViaCyte Raises USD15 Million in Venture Financing 13
Partnerships 14
CRISPR Therapeutics and ViaCyte Enter into Co-Development Agreement 14
ViaCyte Enters into Research Agreement with W. L. Gore & Associates 15
Licensing Agreements 16
ViaCyte Enters into Licensing Agreement with Janssen Biotech 16
Takara Bio Enters into Licensing Agreement with ViaCyte 17
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 18
Nestle Institute of Health Sciences Enters into Licensing Agreement with ViaCyte 19
Debt Offering 20
ViaCyte Raises USD10 million in Convertible Promissory Notes 20
ViaCyte Inc-Key Competitors 21
ViaCyte Inc-Key Employees 22
ViaCyte Inc-Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Government and Public Interest 24
Apr 17, 2018: ViaCyte Awarded NIH SBIR Grant to Support In Vitro Development of Stem Cell-Derived Functional Human Pancreatic Beta Cells 24
Dec 14, 2017: Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency 25
Product News 26
05/22/2017: JDRF and ViaCyte Announce Support for Development of PEC-Direct Cell Replacement Therapy for Type 1 Diabetes 26
02/23/2017: Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapy PEC-Direct for Type 1 Diabetes 27
02/23/2017: Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapy PEC-Encap for insulin-requiring diabetes 28
Product Approvals 29
May 22, 2017: ViaCyte Receives IND Allowance from FDA and Clearance from Health Canada to Commence International Clinical Trial of PEC-Direct Cell Therapy for High-Risk Type 1 Diabetes 29
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31
List Of Figure
List of Figures
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
ViaCyte Inc, Pharmaceuticals & Healthcare, Key Facts 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViaCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViaCyte Inc, Deals By Therapy Area, 2012 to YTD 2018 8
ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ViaCyte Raises USD10 Million in Financing 11
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 12
ViaCyte Raises USD15 Million in Venture Financing 13
CRISPR Therapeutics and ViaCyte Enter into Co-Development Agreement 14
ViaCyte Enters into Research Agreement with W. L. Gore & Associates 15
ViaCyte Enters into Licensing Agreement with Janssen Biotech 16
Takara Bio Enters into Licensing Agreement with ViaCyte 17
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 18
Nestle Institute of Health Sciences Enters into Licensing Agreement with ViaCyte 19
ViaCyte Raises USD10 million in Convertible Promissory Notes 20
ViaCyte Inc, Key Competitors 21
ViaCyte Inc, Key Employees 22
ViaCyte Inc, Subsidiaries 23
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Company Profile
Company Profile Title
Summary
ViaCyte Inc (ViaCyte), formerly Novocell Inc is a regenerative medicine company that centres on the development of cell replacement therapies for the treatment of diabetes. The company's pipeline products portfolio includes VC-01, which is being developed as a therapy for T1D patients who have minimal to no insulin-producing beta cell function; and PEC-Direct, for type 1 diabetes patients that have glycemic lability, hypoglycemic episodes, and impaired hypoglycemia awareness. Its PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device. The company works in partnership with academic, commercial and not-for-profit institutions. ViaCyte is headquartered in San Diego, California, the US.
ViaCyte Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViaCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ViaCyte Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
ViaCyte Raises USD10 Million in Financing 11
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 12
ViaCyte Raises USD15 Million in Venture Financing 13
Partnerships 14
CRISPR Therapeutics and ViaCyte Enter into Co-Development Agreement 14
ViaCyte Enters into Research Agreement with W. L. Gore & Associates 15
Licensing Agreements 16
ViaCyte Enters into Licensing Agreement with Janssen Biotech 16
Takara Bio Enters into Licensing Agreement with ViaCyte 17
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 18
Nestle Institute of Health Sciences Enters into Licensing Agreement with ViaCyte 19
Debt Offering 20
ViaCyte Raises USD10 million in Convertible Promissory Notes 20
ViaCyte Inc-Key Competitors 21
ViaCyte Inc-Key Employees 22
ViaCyte Inc-Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Government and Public Interest 24
Apr 17, 2018: ViaCyte Awarded NIH SBIR Grant to Support In Vitro Development of Stem Cell-Derived Functional Human Pancreatic Beta Cells 24
Dec 14, 2017: Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency 25
Product News 26
05/22/2017: JDRF and ViaCyte Announce Support for Development of PEC-Direct Cell Replacement Therapy for Type 1 Diabetes 26
02/23/2017: Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapy PEC-Direct for Type 1 Diabetes 27
02/23/2017: Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapy PEC-Encap for insulin-requiring diabetes 28
Product Approvals 29
May 22, 2017: ViaCyte Receives IND Allowance from FDA and Clearance from Health Canada to Commence International Clinical Trial of PEC-Direct Cell Therapy for High-Risk Type 1 Diabetes 29
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31
List Of Figure
List of Figures
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
ViaCyte Inc, Pharmaceuticals & Healthcare, Key Facts 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViaCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViaCyte Inc, Deals By Therapy Area, 2012 to YTD 2018 8
ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ViaCyte Raises USD10 Million in Financing 11
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 12
ViaCyte Raises USD15 Million in Venture Financing 13
CRISPR Therapeutics and ViaCyte Enter into Co-Development Agreement 14
ViaCyte Enters into Research Agreement with W. L. Gore & Associates 15
ViaCyte Enters into Licensing Agreement with Janssen Biotech 16
Takara Bio Enters into Licensing Agreement with ViaCyte 17
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 18
Nestle Institute of Health Sciences Enters into Licensing Agreement with ViaCyte 19
ViaCyte Raises USD10 million in Convertible Promissory Notes 20
ViaCyte Inc, Key Competitors 21
ViaCyte Inc, Key Employees 22
ViaCyte Inc, Subsidiaries 23
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020